Keeping Pace in Lung Cancer – All About Antiangiogenics and TKIs: Current Roles and Future Directions in EGFR-Mutant NSCLC - a podcast by ReachMD

CME credits: 0.25

Valid until: 30-11-2022

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-all-about-antiangiogenics-and-tkis-current-roles-and-future-directions-in-egfr-mutant-nsclc/13019/

In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD